Sign in
Back
When to Initiate Disease-Modifying Drugs for Relapsing Remitting Multiple Sclerosis in Adults?
Journal article   Open access  Peer reviewed

When to Initiate Disease-Modifying Drugs for Relapsing Remitting Multiple Sclerosis in Adults?

Mona Alkhawajah and Joel Oger
Multiple sclerosis international, Vol.2011, pp.724871-11
01/01/2011
DOI: https://doi.org/10.1155/2011/724871
PMCID: PMC3195775
PMID: 22096641

Abstract

Clinical Neurology Life Sciences & Biomedicine Neurosciences & Neurology Science & Technology
For patients with Relapsing Remitting Multiple Scierosis Beta Interfaerons and Glatiramer Acetate were the first to be licensed for treatment. This review deals with one major question: when to initiate therapy? Through exploring the unique characteristics of the disease and treatement we suggest an approach that should be helpful in the process of decision-making.
url
https://doi.org/10.1155/2011/724871View
Published (Version of record) Open

Metrics

1 Record Views

Details